COMPANY

EpiVax

HQ: Providence, RI source · epivax.com ↗ · New England

Status: Acquired, now part of SV Health Investors · How status works

EpiVax has received NIH funding, most recently in fiscal 2023 for the project “Validation and Improvement of ISPRI-HCP: An Innovative Platform for Immunogenicity Risk Assessment of Process-related Protein Impurities”. From public records Source · Oct 12, 2026

Keywords: vaccine

Location: Providence, RI · source · Oct 15, 2026

Profile checked Oct 10, 2026

49NIH grants

NIH awards 49

Annual award amounts. Total $19.0M.

Aug 23, 2023 NIH award 1R43IP001225-01 FY2022: $299,930 awarded for that fiscal year; activity R43 (SBIR); PI GRIZOTTE-LAKE, MAYARA; recipient as written: EPIVAX, INC., PROVIDENCE, RI. PA21259, SBIR, Phase I, Improving T cell Res source ↗
Jul 27, 2023 NIH award 1R43AI174486-01 FY2023: $299,917 awarded for that fiscal year; activity R43 (SBIR); PI HALTAUFDERHYDE, KIRK DONALD; recipient as written: EPIVAX, INC., PROVIDENCE, RI. Validation and Improvement of ISPRI-HC source ↗
Aug 24, 2022 NIH award 1U01FD007760-01 FY2022: $1,999,984 awarded for that fiscal year; activity U01 (OTHER_NIH); PI DEGROOT, ANNE SEARLS; recipient as written: EPIVAX, INC., PROVIDENCE, RI. ISPRI-HCP: CHO protein impurity immuno source ↗
Jul 26, 2021 NIH award 5R01AI132205-05 FY2021: $1,123,469 awarded for that fiscal year; activity R01 (OTHER_NIH); PI DEGROOT, ANNE SEARLS; recipient as written: EPIVAX, INC., PROVIDENCE, RI. Structure-Guided Design of CD4 T cell source ↗
Jul 14, 2020 NIH award 5R01AI132205-04 FY2020: $1,136,044 awarded for that fiscal year; activity R01 (OTHER_NIH); PI DEGROOT, ANNE SEARLS; recipient as written: EPIVAX, INC., PROVIDENCE, RI. Structure-Guided Design of CD4 T cell source ↗
Jul 16, 2019 NIH award 5R01AI132205-03 FY2019: $1,148,204 awarded for that fiscal year; activity R01 (OTHER_NIH); PI DEGROOT, ANNE SEARLS; recipient as written: EPIVAX, INC., PROVIDENCE, RI. Structure-Guided Design of CD4 T cell source ↗
Apr 22, 2019 NIH award 5R43TR002441-02 FY2019: $133,578 awarded for that fiscal year; activity R43 (SBIR); PI DEGROOT, ANNE SEARLS; recipient as written: EPIVAX, INC., PROVIDENCE, RI. GAA-ITEM: Personalizing the Prediction of Ant source ↗
Aug 27, 2018 NIH award 5R43DK115365-02 FY2018: $139,842 awarded for that fiscal year; activity R43 (SBIR); PI DEGROOT, ANNE SEARLS; recipient as written: EPIVAX, INC., PROVIDENCE, RI. Novel Antigen-Specific Immunomodulatory Tregi source ↗
Jul 18, 2018 NIH award 5R01AI132205-02 FY2018: $1,150,251 awarded for that fiscal year; activity R01 (OTHER_NIH); PI DEGROOT, ANNE SEARLS; recipient as written: EPIVAX, INC., PROVIDENCE, RI. Structure-Guided Design of CD4 T cell source ↗
May 9, 2018 NIH award 1R43TR002441-01 FY2018: $191,402 awarded for that fiscal year; activity R43 (SBIR); PI DEGROOT, ANNE SEARLS; recipient as written: EPIVAX, INC., PROVIDENCE, RI. GAA-ITEM: Personalizing the Prediction of Ant source ↗
Aug 24, 2017 NIH award 1R43DK115365-01 FY2017: $177,020 awarded for that fiscal year; activity R43 (SBIR); PI DEGROOT, ANNE SEARLS; recipient as written: EPIVAX, INC., PROVIDENCE, RI. Novel Antigen-Specific Immunomodulatory Tregi source ↗
Aug 14, 2017 NIH award 1R01AI132205-01 FY2017: $1,221,150 awarded for that fiscal year; activity R01 (OTHER_NIH); PI DEGROOT, ANNE SEARLS; recipient as written: EPIVAX, INC., PROVIDENCE, RI. Structure-Guided Design of CD4 T cell source ↗
Jun 21, 2017 NIH award 5R43AI118189-02 FY2017: $290,546 awarded for that fiscal year; activity R43 (SBIR); PI DEGROOT, ANNE SEARLS; recipient as written: EPIVAX, INC., PROVIDENCE, RI. Development of a Non-adjuvanted VLP Vaccine a source ↗
Jun 27, 2016 NIH award 1R43AI118189-01A1 FY2016: $300,000 awarded for that fiscal year; activity R43 (SBIR); PI DEGROOT, ANNE SEARLS; recipient as written: EPIVAX, INC., PROVIDENCE, RI. Development of a Non-adjuvanted VLP Vaccine source ↗
Jul 22, 2013 NIH award 5R43AI102454-02 FY2013: $300,000 awarded for that fiscal year; activity R43 (SBIR); PI DEGROOT, ANNE SEARLS; recipient as written: EPIVAX, INC., PROVIDENCE, RI. Inducing Tolerance to Enzyme Replacement Ther source ↗
Jul 1, 2013 NIH award 5R43HL114308-02 FY2013: $376,351 awarded for that fiscal year; activity R43 (SBIR); PI DEGROOT, ANNE SEARLS; recipient as written: EPIVAX, INC., PROVIDENCE, RI. Combined Factor VIII Replacement and Toleranc source ↗
Mar 20, 2013 NIH award 5R44DK081261-04 FY2013: $727,574 awarded for that fiscal year; activity R44 (SBIR); PI DEGROOT, ANNE SEARLS; recipient as written: EPIVAX, INC., PROVIDENCE, RI. EpiVax Phase II SBIR: Preclinical studies of source ↗
Aug 31, 2012 NIH award 1R43AI102454-01 FY2012: $300,000 awarded for that fiscal year; activity R43 (SBIR); PI DEGROOT, ANNE SEARLS; recipient as written: EPIVAX, INC., PROVIDENCE, RI. Inducing Tolerance to Enzyme Replacement Ther source ↗
Jul 10, 2012 NIH award 1R43HL114308-01 FY2012: $381,361 awarded for that fiscal year; activity R43 (SBIR); PI DEGROOT, ANNE SEARLS; recipient as written: EPIVAX, INC., PROVIDENCE, RI. Combined Factor VIII Replacement and Toleranc source ↗
Jul 3, 2012 NIH award 5R21AI090359-02 FY2012: $250,758 awarded for that fiscal year; activity R21 (OTHER_NIH); PI DEGROOT, ANNE SEARLS; recipient as written: EPIVAX, INC., PROVIDENCE, RI. Novel H1N1 influenza protection via cros source ↗
Mar 27, 2012 NIH award 2R44DK081261-03A1 FY2012: $746,662 awarded for that fiscal year; activity R44 (SBIR); PI DEGROOT, ANNE SEARLS; recipient as written: EPIVAX, INC., PROVIDENCE, RI. Preclinical Studies of Tregitope Delivery a source ↗
Apr 28, 2011 NIH award 1R21AI090359-01A1 FY2011: $221,484 awarded for that fiscal year; activity R21 (OTHER_NIH); PI DEGROOT, ANNE SEARLS; recipient as written: EPIVAX, INC., PROVIDENCE, RI. Novel H1N1 influenza protection via cr source ↗
Sep 27, 2010 NIH award 3R21AI078800-02S2 FY2010: $243,561 awarded for that fiscal year; activity R21 (OTHER_NIH); PI DEGROOT, ANNE SEARLS; recipient as written: EPIVAX, INC., PROVIDENCE, RI. Optimization of HIV vaccine subunit de source ↗
Sep 10, 2010 NIH award 3R43HL088834-02S1 FY2010: $173,764 awarded for that fiscal year; activity R43 (SBIR); PI DEGROOT, ANNE SEARLS; recipient as written: EPIVAX, INC., PROVIDENCE, RI. Epitope-driven deimmunization of Factor VII source ↗
Sep 16, 2009 NIH award 3R21AI078800-02S1 FY2009: $215,016 awarded for that fiscal year; activity R21 (OTHER_NIH); PI DEGROOT, ANNE SEARLS; recipient as written: EPIVAX, INC., PROVIDENCE, RI. Optimization of HIV vaccine subunit de source ↗
Aug 21, 2009 NIH award 5R21AI078800-02 FY2009: $202,138 awarded for that fiscal year; activity R21 (OTHER_NIH); PI DEGROOT, ANNE SEARLS; recipient as written: EPIVAX, INC., PROVIDENCE, RI. Optimization of HIV vaccine subunit deli source ↗
Jul 1, 2009 NIH award 5R43DK081261-02 FY2009: $106,439 awarded for that fiscal year; activity R43 (SBIR); PI DEGROOT, ANNE SEARLS; recipient as written: EPIVAX, INC., PROVIDENCE, RI. T1D Tolerance Induction with Natural Treg Epi source ↗
Sep 29, 2008 NIH award 1R21AI078800-01 FY2008: $163,400 awarded for that fiscal year; activity R21 (OTHER_NIH); PI DEGROOT, ANNE SEARLS; recipient as written: EPIVAX, INC., PROVIDENCE, RI. Optimization of HIV vaccine subunit deli source ↗
Aug 18, 2008 NIH award 5R43AI075830-02 FY2008: $285,475 awarded for that fiscal year; activity R43 (SBIR); PI DEGROOT, ANNE SEARLS; recipient as written: EPIVAX, INC., PROVIDENCE, RI. Optimization of a Multivalent Tuberculosis Va source ↗
Jul 18, 2008 NIH award 5R43HL088834-02 FY2008: $264,446 awarded for that fiscal year; activity R43 (SBIR); PI DEGROOT, ANNE SEARLS; recipient as written: EPIVAX, INC., PROVIDENCE, RI. Epitope-driven deimmunization of Factor VIII source ↗